Evaluation of the efficacy of novaluron 0.2 % GR for the control of Aedes (Stegomyia) aegypti (Diptera).

Aedes (Stegomyia) aegypti is the main vector of dengue, zika and chikungunya in the Americas. These diseases have a significant impact on public health. According to the World Health Organization (WHO), controlling these diseases requires a comprehensive approach, and the control of larvae is a part of that strategy. Insect growth regulator (IGR) insecticides stand out as an efficient alternative for facilitating the control of Ae. aegypti at immature stages. The main goal was to evaluate the effectiveness of IGR novaluron 0.2 % GR, in the 50, 90, 95 and 99 lethal concentrations (LC) for fourth-instar larvae of Ae. aegypti in the laboratory. In field conditions, the percentage of inhibition of emergence was estimated by using the LC levels obtained in the laboratory through two methods of water management with refill and without refill in 40 L recipients. The study was carried out in 30 homes in a neighborhood with a high incidence of dengue in Medellin (Antioquia, Colombia). The bioassays completed indicated that LC 50, 90, 95 and 99 corresponded to 0.019, 0.055, 0.065 and 0.084 mg/L, respectively. The field results indicated that novaluron 0.2 % GR efficiently inhibited the emergence of adult Ae. aegypti, suggesting that the product has potential as a population regulator at very low concentrations. The product is considered extremely useful for programs to prevent and control dengue, zika and chikungunya

Guía de práctica clínica para la prevención, diagnóstico, tratamiento y rehabilitación de la falla cardiaca en población mayor de 18 años, clasificación B, C y D

La falla cardíaca es un síndrome clínico caracterizado por síntomas y signos típicos de insuficiencia cardíaca, adicional a la evidencia objetiva de una anomalía estructural o funcional del corazón. Guía completa 2016. Guía No. 53Población mayor de 18 añosN/

Evaluación de la eficacia de novaluron 0,2 % GR para el control de Aedes (Stegomyia) aegypti (Diptera)

Aedes (Stegomyia) aegypti is the main vector of dengue, zika and chikungunya in the Americas. These diseases have a significant impact on public health. According to the World Health Organization (WHO), controlling these diseases requires a comprehensive approach, and the control of larvae is a part of that strategy. Insect growth regulator (IGR) insecticides stand out as an efficient alternative for facilitating the control of Ae. aegypti at immature stages. The main goal was to evaluate the effectiveness of IGR novaluron 0.2 % GR, in the 50, 90, 95 and 99 lethal concentrations (LC) for fourth-instar larvae of Ae. aegypti in the laboratory. In field conditions, the percentage of inhibition of emergence was estimated by using the LC levels obtained in the laboratory through two methods of water management with refill and without refill in 40 L recipients. The study was carried out in 30 homes in a neighborhood with a high incidence of dengue in Medellin (Antioquia, Colombia). The bioassays completed indicated that LC 50, 90, 95 and 99 corresponded to 0.019, 0.055, 0.065 and 0.084 mg/L, respectively. The field results indicated that novaluron 0.2 % GR efficiently inhibited the emergence of adult Ae. aegypti, suggesting that the product has potential as a population regulator at very low concentrations. The product is considered extremely useful for programs to prevent and control dengue, zika and chikungunya.Aedes (Stegomyia) aegypti es el vector principal de dengue, zika y chikungunya en las Américas, enfermedades de gran impacto en salud pública. De acuerdo con la Organización Mundial de la Salud (OMS), el control de estas enfermedades requiere un enfoque integral, y el control larvario hace parte de tal estrategia. Con base en ello, los Insecticidas Reguladores de Crecimiento (IRC) surgen como una alternativa eficiente para el control de los estados inmaduros de este mosquito. Con el propósito de evaluar la eficacia del IRC novaluron 0,2 % GR se determinaron en laboratorio las concentraciones letales (CL) 50, 90, 95 y 99 sobre larvas de cuarto estadio de Ae. aegypti , y en condiciones de campo se estimó el porcentaje de inhibición de emergencia empleando las CL obtenidas en laboratorio, mediante dos esquemas de manejo de agua, con recambio y sin recambio, en recipientes de 40 L, en 30 viviendas en un barrio de Medellín (Antioquia, Colombia) con alta incidencia de dengue. Los bioensayos indicaron que las CL 50, 90, 95 y 99 correspondieron a 0,019; 0,055; 0,065 y 0,084 mg/L, respectivamente. Los resultados de campo revelan que novaluron 0,2 % GR inhibió eficientemente la emergencia de adultos de Ae. aegypti indicando el potencial del producto como regulador de poblaciones a muy bajas concentraciones. Se considera que el producto es de gran utilidad en los programas de prevención y control de dengue, zika y chikungunya

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Abstract Background Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). Methods In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung–Knapp–Sidik–Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Abstract Background Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). Methods In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung–Knapp–Sidik–Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

International audienceSignificance There is growing evidence that preexisting autoantibodies neutralizing type I interferons (IFNs) are strong determinants of life-threatening COVID-19 pneumonia. It is important to estimate their quantitative impact on COVID-19 mortality upon SARS-CoV-2 infection, by age and sex, as both the prevalence of these autoantibodies and the risk of COVID-19 death increase with age and are higher in men. Using an unvaccinated sample of 1,261 deceased patients and 34,159 individuals from the general population, we found that autoantibodies against type I IFNs strongly increased the SARS-CoV-2 infection fatality rate at all ages, in both men and women. Autoantibodies against type I IFNs are strong and common predictors of life-threatening COVID-19. Testing for these autoantibodies should be considered in the general population

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

International audienceSignificance There is growing evidence that preexisting autoantibodies neutralizing type I interferons (IFNs) are strong determinants of life-threatening COVID-19 pneumonia. It is important to estimate their quantitative impact on COVID-19 mortality upon SARS-CoV-2 infection, by age and sex, as both the prevalence of these autoantibodies and the risk of COVID-19 death increase with age and are higher in men. Using an unvaccinated sample of 1,261 deceased patients and 34,159 individuals from the general population, we found that autoantibodies against type I IFNs strongly increased the SARS-CoV-2 infection fatality rate at all ages, in both men and women. Autoantibodies against type I IFNs are strong and common predictors of life-threatening COVID-19. Testing for these autoantibodies should be considered in the general population